Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 7/20 | 1.00 |
| ▸ | CDK8 | P49336 | 3/20 | 1.00 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 1.00 |
| ▸ | SGK1 | O00141 | 4/20 | 0.76 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.76 |
| ▸ | JAK2 | O60674 | 2/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.71 |
| ▸ | PLK4 | O00444 | 1/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
| ▸ | PRKCG | P05129 | 1/20 | 0.71 |
| ▸ | INSR | P06213 | 1/20 | 0.71 |
| ▸ | CDK1 | P06493 | 1/20 | 0.71 |
| ▸ | FES | P07332 | 1/20 | 0.71 |
| ▸ | IGF1R | P08069 | 1/20 | 0.71 |
| ▸ | ROS1 | P08922 | 1/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765160 | 0.92 | CDK8 (0.85) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL8322551 | 0.92 | AXL (0.85) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL15833892 | 0.91 | DYRK1A (0.89) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL3764839 | 0.91 | AXL (0.83) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL8320989 | 0.91 | AXL (0.83) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL3771174 | 0.91 | DYRK1A (0.89) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL13745442 | 0.89 | AXL (0.78) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL8320028 | 0.88 | AXL (0.78) | AXLCDK8TNIKSGK1NTRK1 | |
| SCHEMBL13745948 | 0.87 | AXL (0.76) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL3774587 | 0.87 | AXL (1.00) | AXLCDK8TNIKSGK1CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447093-B2 | 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9447093-B2 | 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9447093-B2 | 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8501446-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | AXL 1252/4885CDK8 142/4885TNIK 68/4885 |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | AXL 1252/4885CDK8 142/4885TNIK 68/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | AXL 1252/4885CDK8 142/4885TNIK 68/4885 |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | DYRK1A, DYRK3, DYRK2 | AXL 3807/4885CDK8 2915/4885TNIK 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.